The rapid diagnostic test provides a
comprehensive solution for detecting canine leishmaniosis that
impacts one in 10 dogs in endemic regions
WESTBROOK, Maine, Nov. 8, 2023
/PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global
leader in pet healthcare innovation, announced the upcoming launch
of the SNAP® Leish 4Dx® Test, a comprehensive
screening test for vector-borne diseases, including canine
leishmaniosis. The SNAP Leish 4Dx Test uses the trusted SNAP 4Dx
Plus testing platform, which detects Lyme disease, heartworm
disease, ehrlichiosis, and anaplasmosis. By replacing Lyme disease
detection with detection of leishmaniosis, a more prevalent endemic
disease in certain regions of the world, the SNAP Leish 4Dx Test
supports vector-borne disease diagnosis globally. The test will be
available in Europe and
Asia beginning February 2024.
Leishmaniosis is a potentially fatal zoonotic disease
transmitted to dogs by sand flies commonly found in tropical and
subtropical regions of Europe,
Asia, Africa, and South and Central America. Early detection is key; any
dog living in or traveling to these endemic regions is susceptible
to infection and should be tested, as the disease can be fatal if
left untreated. Infected dogs can remain asymptomatic for months to
years, making testing for leishmaniosis an essential component of
annual wellness screens.
"In Leishmania-endemic areas globally, where one in 10
dogs tested may be positive, it's critical for practitioners to
screen healthy dogs annually for Leishmania antibodies, along with
other common vector-borne pathogens, using a qualitative,
comprehensive test with sufficient sensitivity and specificity at
the point-of-care," said Professor Guadalupe Miró, DEVPC, Veterinary Faculty,
Universidad Complutense of Madrid,
Spain. "For Leishmania-seropositive dogs, it's also
extremely important to quantify infection level and consider
results from chemistry, CBC differentials, and urinalysis, so
veterinarians can best determine a treatment or monitoring
plan."
The launch of the SNAP Leish 4Dx Test provides veterinarians
with an end-to-end solution for vector-borne disease testing,
including:
- The ability to screen for heartworm disease, ehrlichiosis,
anaplasmosis, and leishmaniosis with a single sample during the
patient visit.
- Streamlined reference laboratory follow-up testing for
quantification of SNAP positives and the opportunity to perform
additional follow-up testing in-clinic or at IDEXX
Reference Laboratories.
- Compatibility with the SNAP Pro® Analyzer,
which supports an efficient practice workflow by automatically
activating and interpreting test results and facilitating seamless
charge capture.
- Ongoing support and education to keep veterinary staff
up-to-date with the latest resources to help protect pets and their
families.
"Parasites and vector-borne diseases like leishmaniosis are an
increasing risk to the health of pets globally," said Jay Mazelsky, IDEXX President and Chief
Executive Officer. "This expansion of our SNAP franchise
demonstrates our commitment to expanding our vector-borne disease
offering to support veterinarians worldwide in their mission to
deliver a higher standard of care for pets."
For more information about the SNAP platform, please visit
idexx.com/en/veterinary/products/snap-tests/
About IDEXX
IDEXX is a global leader in pet healthcare innovation. Our
diagnostic and software products and services create clarity in the
complex, constantly evolving world of veterinary medicine. We
support longer, fuller lives for pets by delivering insights and
solutions that help the veterinary community around the world make
confident decisions—to advance medical care, improve efficiency,
and build thriving practices. Our innovations also help ensure the
safety of milk and water across the world and maintain the health
and well-being of people and livestock. IDEXX Laboratories, Inc. is
a member of the S&P 500® Index. Headquartered in
Maine, IDEXX employs nearly 11,000
people and offers solutions and products to customers in more than
175 countries and territories. For more information about IDEXX,
visit idexx.com.
Note Regarding Forward-Looking Statements
This news
release contains or may contain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by the use of
words such as "expects," "may," "anticipates," "intends," "would,"
"will," "plans," "believes," "estimates," "should," "project," and
similar words and expressions. These forward-looking statements are
intended to provide our current expectations or forecasts of future
events; are based on current estimates, projections, beliefs, and
assumptions; and are not guarantees of future performance. Actual
events or results may differ materially from those described in the
forward-looking statements. These statements are subject to risks,
uncertainties, assumptions, and other important factors. Readers
are cautioned not to put undue reliance on such forward-looking
statements because actual results may vary materially from those
expressed or implied. The reports filed by IDEXX pursuant to
United States securities laws
contain discussions of some of these risks and uncertainties. IDEXX
assumes no obligation to, and expressly disclaims any obligation
to, update or revise any forward-looking statements, whether as a
result of new information, future events, or otherwise. Readers are
advised to review IDEXX's filings with the United States Securities
and Exchange Commission (which are available from the SEC's EDGAR
database at sec.gov and via IDEXX's website at idexx.com).
View original content to download
multimedia:https://www.prnewswire.com/news-releases/idexx-expands-snap-platform-with-leish-4dx-test-to-support-veterinarians-globally-in-diagnosing-vector-borne-diseases-301978168.html
SOURCE IDEXX Laboratories, Inc.